公开(公告)号：WO2007084667A2

公开(公告)日：2007-07-26

申请号：PCT/US2007/001439

申请日：2007-01-18

Applicant: OSI PHARMACEUTICAL, INC. ,  ARNOLD, Lee, D. ,  CHEN, Xin ,  DONG, Hanping ,  GARTON, Andrew ,  MULVIHILL, Mark, Joseph ,  SMITH, Colin Peter, Sambrook ,  THOMAS, Gerard, Hugh ,  KRULLE, Thomas, Martin ,  WANG, Jing

Inventor： ARNOLD, Lee, D. ,  CHEN, Xin ,  DONG, Hanping ,  GARTON, Andrew ,  MULVIHILL, Mark, Joseph ,  SMITH, Colin Peter, Sambrook ,  THOMAS, Gerard, Hugh ,  KRULLE, Thomas, Martin ,  WANG, Jing

IPC: C07D471/04 ,  A61K31/437 ,  A61P35/00

CPC classification number: C07D471/04

Abstract: Compounds of the formula (I) and pharmaceutically acceptable salts thereof, wherein X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , R 1 , and Q 1 are defined herein, inhibit kinase enzymes and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer. The compounds are also useful in the treatment of inflammation, allergy, asthma, disease and conditions of the immune system, disease and conditions of the nervous system, cardiovascular diseases, disease and conditions of the eye, dermatological diseases, osteoporosis, diabetes, multiple sclerosis, and infections.

Abstract translation: 式（I）化合物及其药学上可接受的盐，其中X 1，X 2，X 3，X 4， X 1，X 5，X 6，X 7，R 1和Q 1 本文定义抑制激酶，并且可用于治疗和/或预防过度增殖性疾病如癌症。 该化合物还可用于治疗炎症，过敏，哮喘，免疫系统的疾病和状况，神经系统的疾病和状况，心血管疾病，眼睛疾病和病症，皮肤病，骨质疏松症，糖尿病，多发性硬化 和感染。

公开(公告)号：WO2007084667A3

公开(公告)日：2007-12-06

申请号：PCT/US2007001439

申请日：2007-01-18

Applicant: OSI PHARMACEUTICAL INC ,  ARNOLD LEE D ,  CHEN XIN ,  DONG HANPING ,  GARTON ANDREW ,  MULVIHILL MARK JOSEPH ,  SMITH COLIN PETER SAMBROOK ,  THOMAS GERARD HUGH ,  KRULLE THOMAS MARTIN ,  WANG JING

Inventor： ARNOLD LEE D ,  CHEN XIN ,  DONG HANPING ,  GARTON ANDREW ,  MULVIHILL MARK JOSEPH ,  SMITH COLIN PETER SAMBROOK ,  THOMAS GERARD HUGH ,  KRULLE THOMAS MARTIN ,  WANG JING

IPC: C07D471/04 ,  A61K31/437 ,  A61P35/00

CPC classification number: C07D471/04

Abstract: Compounds of the formula (I) and pharmaceutically acceptable salts thereof, wherein X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , R 1 , and Q 1 are defined herein, inhibit kinase enzymes and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer. The compounds are also useful in the treatment of inflammation, allergy, asthma, disease and conditions of the immune system, disease and conditions of the nervous system, cardiovascular diseases, disease and conditions of the eye, dermatological diseases, osteoporosis, diabetes, multiple sclerosis, and infections.

Abstract translation: 式（I）化合物及其药学上可接受的盐，其中X 1，X 2，X 3，X 4， X SUB 5，SUB 6，SUB 7，SUB 1和SUP 1 本文定义为抑制激酶，并可用于治疗和/或预防过度增殖性疾病如癌症。 这些化合物还可用于治疗炎症，变态反应，哮喘，疾病和免疫系统疾病和病症，神经系统疾病和病症，心血管疾病，眼睛疾病和病症，皮肤病，骨质疏松症，糖尿病，多发性硬化症 和感染。

公开(公告)号：ZA200303729B

公开(公告)日：2004-05-14

申请号：ZA200303729

申请日：2003-05-14

Applicant: OSI PHARMACEUTICAL INC

Inventor： CASTELHANO ARLINDO L ,  MCKIBBEN BRYAN ,  WITTER DAVID J

IPC: A61K20060101 ,  A61K9/08 ,  A61K31/519 ,  A61K45/00 ,  A61P20060101 ,  A61P5/46 ,  A61P7/00 ,  A61P9/00 ,  A61P9/04 ,  A61P9/06 ,  A61P9/08 ,  A61P11/00 ,  A61P11/02 ,  A61P11/06 ,  A61P11/08 ,  A61P13/12 ,  A61P25/00 ,  A61P25/16 ,  A61P25/20 ,  A61P25/28 ,  A61P27/02 ,  A61P27/06 ,  A61P29/00 ,  A61P37/08 ,  A61P39/06 ,  A61P43/00 ,  C07D20060101 ,  C07D487/04 ,  C07D ,  A61K ,  A61P

公开(公告)号：BR0215279A

公开(公告)日：2005-05-10

申请号：BR0215279

申请日：2002-12-20

Applicant: OSI PHARMACEUTICAL INC

Inventor： CASTELHANO ARLINDO L ,  MCKIBBEN BRYAN

IPC: A61K31/519 ,  A61P1/04 ,  A61P1/12 ,  A61P3/10 ,  A61P9/00 ,  A61P9/10 ,  A61P9/12 ,  A61P11/06 ,  A61P13/00 ,  A61P17/00 ,  A61P17/04 ,  A61P19/02 ,  A61P27/02 ,  A61P29/00 ,  A61P35/00 ,  A61P35/04 ,  A61P37/08 ,  A61P43/00 ,  C07D487/04

Abstract: A compound having the structure wherein, R1 is a substituted or unsubstituted alkyl, wherein the substituent is hydroxyl, dihydroxy, carboxyl, -C(=O)NRaRb, -NRaRb, -NRaC(=O)NRaRb, -NRaC(=O)ORa, -OC(=O)NRaRb, or -NHC(=O)Ra; R2 is hydrogen or a substituted or unsubstituted alkyl, wherein the substituent is hydroxyl, dihydroxyl, carboxyl, -C(=O)NRaRb, -NRaRb, -NRaC(=O)NRaRb, -NRaC(=O)ORa, -OC(=O)NRaRb, or -NHC(=O)Ra, or R1, R2 and N together form a substituted piperazine, substituted azetidine ring, or a pyrrolidine ring substituted with -(CH2)2OH or -CH2C(=O)OH; R3 is a substituted or unsubstituted phenyl or a 5-6 membered heteroaryl ring, wherein the substituent is halogen, hydroxyl, cyano, (C1-C15)alkyl, (C1-C15)alkoxyl, or -NRaRb; R4 is hydrogen or substituted or unsubstituted (C1-C15)alkyl; R5 is -(CH2)mOR6, -CHNOR7, -C(=O)NR8R9, -(CH2)mC(=O)OR10, -(CH2)kC(=O)NR11R12.